# Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology

> **NCT03498183** · PHASE2,PHASE3 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 372 (actual)

## Conditions studied

- Malignancy of Thyroid Nodules

## Interventions

- **DRUG:** MIBI-Tc99m/Iodine-123

## Key facts

- **NCT ID:** NCT03498183
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2025-05-07
- **Final completion:** 2025-05-07
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03498183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03498183, "Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03498183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*